Loading
A phase 2 trial of AL8326 40 mg in small-cell lung cancer, renal cell carcinoma and non-small-cell lung cancer, run by Advenchen Pharmaceuticals, LLC., now recruiting.
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment is a phase 2 interventional study registered as NCT05363280 by Advenchen Pharmaceuticals, LLC., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-12. Interventions recorded: AL8326 40 mg, AL8326 60 mg and AL8326 80 mg--stopped.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advenchen Laboratories, Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Advenchen Laboratories and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/